Lilly Reports $36.5B Tirzepatide Revenue as Canada Awaits Generics
Eli Lilly reported combined tirzepatide revenue of $36.5 billion across Mounjaro and Zepbound, with Mounjaro sales surging 99% year-over-year to nearly $23 billion while Zepbound revenue soared 175% to roughly $13.5 billion.
Record Tirzepatide Sales Drive Growth
The pharmaceutical giant's latest financial results highlight the massive market demand for tirzepatide-based medications. Mounjaro, initially approved for diabetes management, generated the larger revenue share at $23 billion, while Zepbound, the same compound marketed for different indications, contributed $13.5 billion.
Canadian pharmacies currently list Mounjaro starting at $301 monthly, while Zepbound pricing begins at $435 monthly according to recent price comparisons. Both medications contain the same active ingredient, tirzepatide, manufactured by Eli Lilly.
Canadian Market Context
The revenue surge comes as Canadian patients face significant out-of-pocket costs for tirzepatide medications. Major pharmacy chains including Shoppers Drug Mart, Costco, and Walmart stock both formulations, with pricing varying by location and dose strength.
Unlike semaglutide medications such as Ozempic and Wegovy, which face patent expiration in January 2026, Lilly's tirzepatide compounds maintain patent protection with no imminent generic competition expected in Canada.
Generic Competition Timeline
Health Canada is currently reviewing nine generic semaglutide applications from manufacturers including Sandoz, Apotex, and Teva. However, tirzepatide generics remain years away, providing Eli Lilly continued market exclusivity for Mounjaro and Zepbound formulations.
The company recently reduced Canadian prices for both medications by 20% or more, effective December 29, 2025, in what analysts view as a preemptive move to maintain market share ahead of eventual competition.
Provincial Coverage Decisions Pending
Canada's Drug Agency continues evaluating public coverage recommendations for tirzepatide medications. Current estimates suggest annual costs could reach $5,000 based on maintenance dosing, making insurance coverage a critical factor for patient access.
Alberta Blue Cross and other provincial plans are monitoring generic semaglutide approvals before making decisions on tirzepatide coverage, according to industry reports.
Market Implications
The revenue figures underscore the substantial market size for GLP-1 receptor agonist medications globally. Canadian patients can track current pricing and availability through our generic semaglutide tracker while awaiting Health Canada approval decisions.
Industry observers note that Lilly's strong tirzepatide performance positions the company advantageously as Novo Nordisk faces generic competition for its semaglutide portfolio starting in 2026.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
